The costs of depression.

Area of Science:

• Mental Health Research
• Epidemiology
• Health Economics

Background:

• Major depression (MDD) is a prevalent, persistent, and burdensome global disorder with early onset.
• MDD is associated with numerous adverse outcomes, suggesting significant causal effects on overall burden.
• Existing evidence supports the cost-effectiveness of expanded depression treatment from societal and employer perspectives.

Purpose of the Study:

• To review the global burden and treatment landscape of major depression.
• To evaluate the cost-effectiveness of workplace depression treatment programs.
• To highlight the gap between recommended and actual treatment rates for MDD.

Main Methods:

• Analysis of epidemiological survey data from multiple countries (e.g., WMH surveys).
• Review of randomized, large-scale workplace depression treatment effectiveness trials in the US.
• Examination of treatment rates and adherence to guidelines for MDD.

Main Results:

• Workplace depression treatment trials demonstrated positive returns on investment for employers.
• Despite proven effectiveness, a significant proportion of individuals with MDD in the US and globally do not receive treatment.
• Treatment rates are lower in other developed countries and substantially lower in developing nations, with gaps also noted in patients with chronic physical disorders.

Conclusions:

• Expanded depression care management programs have seen some adoption but treatment access remains insufficient.
• Further research, including RCTs, is needed to understand depression treatment effects in chronic physical illness populations.
• Long-term effectiveness trials are crucial to assess early MDD interventions' impact on life course and secondary conditions.